FORT WORTH, Texas (PRWEB) May 15, 2018
The Center for Cancer and Blood Disorders is now offering SpaceOAR hydrogel, an innovative product for men choosing to undergo radiation therapy for prostate cancer. Applied during a minimally invasive procedure, the hydrogel acts as a protective spacer between the prostate and the rectum and has been clinically proven to reduce the risk of side effects from radiation treatment.
At The Center for Cancer and Blood Disorders, board-certified physicians provide cancer treatment to more than 12,000 patients annually at multiple locations in North Texas. Offered are the latest advances in chemotherapy, radiation therapy, immunotherapy, hormonal therapy, and biological therapy. The opportunity is also offered for patients to take advantage of groundbreaking cancer treatments available only through clinical trials and cancer research. The Center for Cancer and Blood Disorders is a Cyberknife facility that offers a variety of treatments including the unique treatment of hypofractionation with SBRT as well as brachytherapy for the treatment of prostate cancer.
Outstanding medical care, combined with compassion and concern are the main focuses for The Center for Cancer and Blood Disorders, while also organizing spiritual and emotional cancer support programs to help patients cope with the feelings, hopes, and fears that often come with cancer treatment.
"SpaceOAR is an ingenious advancement for patients receiving radiation therapy for prostate cancer. It is a simple, outpatient procedure that greatly reduces treatment-related side effects,” said Dr. Matthew Cavey, Radiation Oncologist.
In April 2015, the Food and Drug Administration (FDA) cleared SpaceOAR hydrogel. In a prospective, randomized, multi-center clinical trial in the United States, patients treated with SpaceOAR hydrogel prior to prostate cancer radiation treatment demonstrated bowel, urinary, and sexual benefits through three years of follow-up. The study found that the patients that did not receive SpaceOAR hydrogel experienced a clinically significant decline in bowel, urinary, and sexual quality of life eight times more often than patients that received the procedure. (1, 2)
The SpaceOAR procedure requires local or general anesthesia. Patients can immediately resume their normal activities upon completing the procedure. The gel stays in place for approximately three months and is then naturally absorbed and cleared in the urine in about six months.
“In 2018, there will be over 160,000 new cases of prostate cancer in American men and so far, over 20,000 patients worldwide have been successfully treated with SpaceOAR hydrogel,” said Augmenix President and CEO John Pedersen. “We are excited that The Center for Cancer and Blood Disorders is now offering SpaceOAR hydrogel to their prostate cancer patients.”
1) DA Hamstra, N Mariados, J Sylvester, et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys; 2017 Apr 1; 97(5): 976-985
2) DA Hamstra, et al. Sexual Quality of Life Following Prostate Intensity Modulated Radiotherapy (IMRT) with a Rectal/Prostate Spacer: Secondary Analysis of a Phase III Trial. Published online: July 19, 2017 Practical Radiation Oncology.
Risks associated with the implantation of SpaceOAR hydrogel:
In addition to the risks associated with any medical procedure there are potential complications that may be associated with the use of the SpaceOAR System that include, but are not limited to: pain or discomfort associated with SpaceOAR hydrogel; needle penetration or injection of SpaceOAR hydrogel into the bladder, prostate, rectal wall, rectum or urethra; local inflammatory reactions; infection; injection of air, fluid or SpaceOAR hydrogel intravascularly; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding, constipation; and rectal urgency.